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Since the first AIDS case was diagnosed in 1981, 20 million people have
died from AIDS and 37.8 million people worldwide are living with HIV.
If the current epidemiological trends continue, by 2020, AIDS will have
claimed up to 100 million lives, making it the worst pandemic in human
history. Women bear a disproportionate burden both as caregivers and
as people living with HIV.
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Chair of the Board
In 2004, we saw the world turn its attention to the unique challenges faced by women in the developing world in
their fight against HIV/AIDS. At both Microbicides 2004 in London and the XV International AIDS Conference in
Bangkok, microbicides were featured as never before as a potential woman-initiated prevention method.
It is clear that the HIV pandemic affects all cultures, genders and ages, but World AIDS Day 2004—Women and
Girls, HIV and AIDS —was a reminder to us all that women face many unique obstacles in HIV prevention. The day
was one of sobering reality as we read the statistics on HIV infection in women. HIV/AIDS is affecting women
most severely in places where heterosexual sex is a dominant mode of HIV transmission, as in sub-Saharan Africa
where women and girls make up almost 57 percent of adults (15-49) living with HIV.
The microbicide field has made great strides recently. Five candidate microbicides entered, or are about to enter,
large-scale efficacy trials. The International Partnership for Microbicides (IPM) and others are now focusing on
second-generation microbicides that are specifically active against HIV and products that will combine two or more
drugs in the same formula, as well as extended release delivery devices such as vaginal rings. Several such
products entered early safety trials in 2004.
Yet, the microbicide field still faces significant challenges over the next several years. In addition to the need for
additional clinical trial capacity and increased global awareness of microbicides, a richer pipeline of products is
necessary so strong candidates can be identified and marshalled through the development process. This will
require a substantial increase in government investment into national research programmes, developers, and publicprivate partnerships to develop and test products. In addition, incentives need to be established to encourage
greater participation and investment from the pharmaceutical industry in the development of new microbicides that
meet the HIV prevention needs of developing countries.
While there are many challenges ahead, I am confident that IPM is poised to make a significant contribution. We
look forward to many years of progress.

Els Borst-Eilers, M.D., Ph.D.
Chair of the Board
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Chief Executive Officer
I am pleased to present the first Annual Report from IPM. Since our creation in 2002, we have worked tirelessly to
establish IPM as a resource for microbicide development so that new prevention options can be accelerated.
This past year proved to be a significant turning point for microbicides as female-initiated methods of prevention
gained increased attention from global leaders and policy makers and microbicides garnered headlines around
the world as an important prevention option for women.
In 2004, IPM continued its growth and expanded its capacity to provide resources to help fill gaps in microbicide
development. By screening compounds, designing optimal formulations, establishing manufacturing capacity,
developing trial sites, and conducting access studies, IPM has collaborated with others to provide a wealth of
resources and expertise to those working to develop microbicides. An especially noteworthy accomplishment this
year was the first clinical trial of a microbicide-containing vaginal ring.
The partnerships and collaborative efforts initiated among public and private sector and non-profit entities
incorporate the best practices of each to advance microbicide development. We have built relationships and
brokered innovative agreements with a variety of outstanding groups including academic institutions, pharmaceutical
and biotechnology companies, non-governmental organizations and international organizations to reach a shared
objective to make microbicides for women a reality. IPM was also fortunate to build relationships with several
influential champions who helped to spread the message of microbicides.
In 2004, IPM expanded considerably, acquiring greater international expertise by adding new staff and
consultants, securing larger headquarters in Silver Spring, Maryland, USA and establishing IPM Belgium. We
have been fortunate to work under the guidance and direction of a farsighted and committed Board of Directors.
In 2004, our founding Chairman, Dr. Mahmoud Fathalla, handed the Board Chair to Dr. Els Borst-Eilers, who will
help lead IPM into the next phase of organizational development and field support. I want to take this opportunity
to thank Dr. Fathalla for his stewardship during this critical period of growth for the organization and welcome Dr.
Borst-Eilers in her role as Board Chair and Dr. Alex Coutinho in his new role as Vice-Chair.
I also want to extend my appreciation to our donors who have infused this organization not just with funding
support, but with the confidence and expectation that IPM will play a major role in accelerating microbicide
development and access. Building upon our solid foundation, I look forward to a productive and rewarding 2005.

Zeda F. Rosenberg, Sc.D.
Chief Executive Officer

3

MISSION
The mission of IPM is to prevent HIV transmission by
accelerating the development and availability of safe and effective
microbicides for use by women in developing countries.

WHAT IS A MICROBICIDE?
Microbicides are products that could be applied topically to the vagina to reduce the
transmission of HIV during sexual intercourse. Microbicides could take the form of a gel,
cream, film, suppository, sponge or vaginal ring that releases the active ingredient
gradually, or a new formulation or delivery method yet to be invented.
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Overview
Since the first AIDS case was diagnosed in 1981, 20 million people have died from
AIDS and 37.8 million people worldwide are living with HIV. If current trends continue,
by 2020, AIDS will have claimed up to 100 million lives, making it the worst pandemic in
human history.
Increasingly, in Africa, and in many developing countries in Asia and Latin America, AIDS
is taking a disproportionate toll on women. As a result, AIDS has become one of the
most serious women's health issues globally.
An effective microbicide could not only protect women against HIV infection, but also
interrupt the cycle of transmission from and to men and to newborns by preventing
infection in the mothers. In order to protect individuals, preserve families and control the
spread of the disease, IPM is focused on the population at greatest risk of becoming
infected by HIV: women in developing countries.
IPM was created to identify and address gaps or bottlenecks in the development of and
subsequent access to microbicides. Since its founding in 2002, IPM continues to
establish collaborations based on cost-efficient and rapid approaches to development of
highly promising drugs, conduct state-of-the-art research to optimize formulations and
delivery methods, and develop clinical trial sites to facilitate the future conduct of largescale efficacy studies.
IPM assists microbicide development in multiple ways. One is direct financial support to
organizations involved in drug or formulation development. The second is drug
development services provided by IPM's extensive infrastructure. The third is through
direct development, testing, and clinical trials of promising candidates by IPM.
Î PERCENT OF ADULTS (15-49) LIVING WITH HIV WHO ARE FEMALE, 1985•2004
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Î INTERNATIONAL PARTNERSHIP FOR MICROBICIDES RESOURCES
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IPM growth
IPM grew tremendously as an organization, from a staff of two in 2002 to an international
staff of 23 and a wealth of expert consultants in 2004. As of the writing of this annual
report, the senior management team consists of Dr. Zeda Rosenberg as the Chief
Executive Officer, with Dr. Mark Mitchnick, Chief Scientist, and Ms. Patricia Meier, Chief
Operating Officer/Chief Financial Officer, reporting to her directly. The senior
management team also includes Dr. Paul Coplan, Executive Director for Regulatory
Affairs, Dr. Joseph Romano, Executive Director for Research and Development (R&D),
and Mr. Martin Methot, Executive Director for External Affairs and Policy.
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In addition to expanding its headquarters in Silver Spring, Maryland, USA, IPM Belgium
established an office in Brussels, Belgium in September 2004. With a presence in
Europe, IPM is now positioned to strengthen links with European countries and the
European Union institutions, and to reach out to other constituencies in Europe.

Î OPPORTUNITIES FOR ACTION
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Collaboration with the
Pharmaceutical Industry
In March 2004, IPM and Tibotec Pharmaceuticals Ltd., a subsidiary of
Johnson & Johnson, signed a groundbreaking agreement empowering
IPM to develop the promising compound TMC120 as a microbicide.
This agreement marked the first collaboration in the microbicide field
between a major pharmaceutical company and a public-private
partnership such as IPM.
Building upon Tibotec's Phase I TMC120 gel study, IPM sponsored a
safety trial of TMC120 formulated in a vaginal ring in collaboration with Tibotec and
the Population Council. This was the first human trial of a microbicide in a vaginal ring.
The trial was completed in early 2005.
In late 2004, the R&D team undertook reformulation of the gel, which will be tested in
an expanded safety trial in Rwanda, Tanzania and South Africa, scheduled to begin in
mid-2005. Although the development efforts have been transferred to IPM, Tibotec is
an active member of the TMC120 development team. IPM and Tibotec continue to
work collaboratively on projects as they arise and hold regular joint development team
meetings. This is seen as a model of best practices and will hopefully encourage other
pharmaceutical companies to follow suit.

Microbicidal Vaginal Ring
The TMC120 vaginal ring trial was the first time a microbicide ring formulation was tested
clinically. This study took nine months from concept until the last participant completed
the study. The purpose of the trial was to evaluate whether a vaginal ring can be feasibly
used to deliver TMC120 to the entire vaginal mucosa. Results from this study will be
available in 2005.
As a product moves from R&D to clinical testing, the handoff between the two teams can
be cumbersome especially for a new organization. In its first such experience, IPM's R&D
and Clinical teams worked seamlessly to bring this trial to the clinic in record time.
Production, in cooperation with the Population Council, protocol design, subcontractor
relationships and regulatory support all required participation by many team members.
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Microbicide Research and
Development
IPM has examined the microbicide pathway, from drug discovery to development, and
has identified ways to accelerate efforts to get safe, effective microbicides in the hands of
women in developing countries.
IPM is applying new discoveries in HIV science to the identification and screening of
promising drugs and concentrating resources on the highest priority second- and thirdgeneration microbicide candidates—highly-active antiretroviral single agents as well as
combinations. In collaboration with pharmaceutical companies, biotechnology
companies, non-profit organizations and academia, IPM is funding, in whole or in part,
the development of several microbicide products and enabling technologies. IPM will
continue to seek and add promising approaches to the portfolio of candidates.
One critical factor for success is the engagement of the private sector and academia in
identifying new potential microbicides. In 2004, IPM entered into several critically
important agreements.

"The development and marketing of an effective microbicide could have a great impact on the
well-being of our country's women, and consequently on the children they bear."
DR. MANTO TSHABALALA-MSIMANG, MINISTER OF HEALTH, SOUTH AFRICA

In March 2004, IPM signed a non-exclusive licensing agreement with Tibotec
Pharmaceuticals Ltd., a Belgian-based subsidiary of Johnson & Johnson, to develop
TMC120 as a microbicide (see page 8). Quickly following, in September 2004, IPM
signed an agreement with GlaxoSmithKline to test promising new anti-HIV compounds as
potential microbicides. IPM also has entered into contracts with Biosyn, Inc. for
development of Cyanovirin-N, an HIV fusion inhibitor and with Warner Chilcott and
Queen’s University of Belfast for investigation of microbicide-containing vaginal rings.
Finally, IPM has an agreement with the University of Utah to pursue controlled-release
technologies. These collaborations are precedent-setting ventures based on innovative
intellectual property strategies that will serve as models for future negotiations and
partnerships to accelerate microbicide development. IPM continues to actively seek out
collaborations with the pharmaceutical industry.
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IPM now has several key resources including a formulation facility dedicated to
microbicides and a manufacturing facility capable of producing clinical trial material
under good manufacturing practices for Phase I and Phase II trials. In addition, IPM
supports a dedicated staff at St. George’s Hospital Medical School in London, UK for
the candidate screening programme, and a preclinical testing facility for non-human
primate efficacy studies.

Î PIPELINE
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Other candidates also exist, including many proteins with multiple mechanisms of action and reverse transcriptase inhibitors.
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Clinical Trials and
Capacity Building
To adequately demonstrate efficacy of a candidate microbicide, clinical trials involving
large numbers of women need to be conducted in locations where new HIV infections
occur at a high rate. Additionally, in order to enable clinical trials to lead to product
registration, it is necessary that these studies be conducted according to universally
accepted regulatory guidelines, so as to guarantee the ethical and scientific integrity of
the results and protect trial participants.
IPM’s goals include accelerating the clinical development of promising candidate
microbicides; expanding clinical trial capacity for HIV prevention trials by identifying and
developing new sites; working with local communities where trials are conducted so that
they have a voice and sense of ownership in the clinical trials; and, building political
support and national regulatory authority awareness regarding microbicide clinical
development.

"[Microbicides are] a product still in development. A lot of research is done and it will take a few years
before they can come on the market. But I don't know of any other technology that would make such a
difference to stop the heterosexual spread of HIV."
DR. PETER PIOT, EXECUTIVE DIRECTOR, JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS
The Clinical Team began in 2004 to prepare for a 42-day TMC120 vaginal gel safety
trial expected to start in mid-2005 in three African countries: South Africa, Rwanda and
Tanzania. The trial will be conducted in South Africa in collaboration with FARMOVSParexel in Bloemfontein and the University of Witwatersrand’s Reproductive Health and
HIV Research Unit; in Rwanda, with Projet Ubuzima, a non-governmental organization,
and the Netherlands-based International Antiviral Therapy Evaluation Center (IATEC); and
with the Harvard School of Public Health and the Kilimanjaro Reproductive Health
Programme in Moshi, Tanzania.
IPM is also preparing to conduct an extended safety study on TMC120 gel in Uganda
to begin in late 2005. This will be conducted in collaboration with the MRC/UVRI
Uganda Research Unit and the Medical Research Council Clinical Trials Unit. In 2005,
IPM will also conduct a second vaginal ring study using a new ring formulation.
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Î IPM CLINICAL STUDIES
IPM has been working on the following TMC120 studies.

STUDY

STUDY NAME

IPM001

Vaginal ring trial
 Belgium

Population Council
SGS-Medisearch International N.V.
University of Ghent

IPM002

HIV incidence studies
 Kenya

Family Health International

IPM003

Gel safety trial
 South Africa
 Rwanda
 Tanzania

IPM004

n*

STATUS
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Completed

2,250

Planned 2005

Central Laboratory Services
FARMOVS-Parexel
Harvard School of Public Health
International Antiviral Therapy
Evaluation Center
Kilimanjaro Reproductive Health
Programme
Projet Ubuzima
Quintiles - South Africa
Triclinium
University of Witwatersrand,
Reproductive Health and HIV
Research Unit

112

Planned 2005

Gel pharmacokinetic trial
 South Africa

FARMOVS-Parexel
Triclinium

18

Planned 2005

IPM005

Gel expanded safety trial
 Uganda

MRC/UVRI Uganda Research Unit
Medical Research Council Clinical
Trials Unit - UK
Quintiles - South Africa

200

Planned 2005

IPM006

Gel male tolerance trial
 United States

CONRAD
Family Health International

36

Planned 2005

IPM007

Seroconverter protocol
 Various sites

Quintiles - South Africa
Triclinium

N/A

Planned 2005

IPM008

Vaginal ring trial
 Belgium

SGS-Medisearch International N.V.
University of Ghent
Warner Chilcott

13

Planned 2005

IPM009

Gel efficacy trial

Various

9,824

Planned 2006

* Number of participants
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COLLABORATORS

Regulatory Pathways for
Microbicides
Working towards regulatory approval of microbicides involves assessing the current approaches of
regulatory agencies in Europe and the United States; reviewing regulatory requirements in key
developing countries whose decisions often influence other countries; and developing review and
approval strategies that appropriately consider risk/benefit analyses for microbicide products in
settings where HIV incidence is high.
Among the regulatory challenges to testing and licensing microbicides is the limited experience in
evaluating topical drugs designed to prevent intravaginal infection. Insufficient resources and
expertise in national regulatory authorities (NRAs) in many developing countries are an added
challenge. As a result, NRAs may have to rely on decisions by European and US regulators,
whose decision-making criteria—especially with regard to risks and benefits—may not be
appropriate in settings where HIV prevalence is much higher than in the populations of Europe or
the United States.

"Women and girls need methods to protect themselves from HIV—methods that they can control.
One of the most promising female-controlled prevention options on the horizon is microbicides …"
AILEEN CARROLL, MINISTER OF INTERNATIONAL COOPERATION, CANADA

In June 2004, IPM published a paper in Science magazine on regulatory pathways for licensure
of microbicides. The article outlines the unique challenges that will be faced by microbicide
developers in seeking licensure and calls for strengthening of national regulatory agencies to ensure
country-appropriate risk-benefit assessment.
To overcome regulatory challenges, IPM is working to strengthen capacity in developing countries
in collaboration with organizations, such as the World Health Organization, familiar with multicountry regulatory processes. In addition, to enable joint reviews of products, IPM is creating
stronger collaborative links between NRAs in developing and industrialized countries. Finally, IPM
is liaising with the US Food and Drug Administration (FDA) and the European Medicines Agency
(EMEA) to facilitate regulatory approvals by these agencies and to ensure that microbicide
development programmes meet these requirements.
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IPM is also working with Social & Scientific Systems to establish a database of regulatory
requirements for approval of microbicides in key developing countries, which will be available
online.
IPM's Regulatory Affairs Team made considerable progress in 2004 in researching and preparing
the required documentation to begin clinical trials. IPM recently submitted a clinical trial application
for approval to the Medicines Control Council in South Africa and is preparing to submit a preinvestigational new drug approval to the FDA. These documents and subsequent approvals are a
first step in conducting trials.

Product Attribute Study
IPM has commissioned an acceptability study aimed at determining women's
preferences for a variety of gels. The goal is to take a consumer approach to
ensure that once a microbicide is formulated into a gel, it will be acceptable
to, and used by, women.
South African and US market research firms will team with local partners in
Botswana, Nigeria, South Africa and Zambia to conduct the study. Not to be
confused with a clinical trial that tests microbicide safety and effectiveness, or
a hypothetical acceptability study, women will actually use different gels.
These gels do not contain any active ingredients. To get a representative
sample, different ethnic groups in each country will be included. Women will
be asked to comment upon their likes and dislikes; rate each product on a
range of comfort and aesthetic attributes; describe their likelihood of future use
and whether they would recommend it to others; and provide suggestions for
improvement.
Gathering this type of information will help IPM produce gels that best meet
women's product preferences and will maximize product use. The results will
be shared widely with all microbicide developers.
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Preparing for Access and Use
Ensuring rapid and widespread access to microbicide products is a cross-cutting issue that
influences all of IPM's work. For example, agreements on intellectual property and pricing that
facilitate availability and affordable pricing are conditions of IPM's investment decisions. To further
its access work, IPM has engaged an executive recruiting firm to assist in a search for a Senior
Advisor for Access. The person who ultimately takes on this job will report directly to the Chief
Executive Officer and will play an integral role across the organization.
IPM is working to ensure that women will have access to microbicide products once they have
been tested and approved. Preparing for access considers all steps: from product selection to an
individual woman's interest and ability to use a microbicide product. In advance of the
introduction of microbicides, IPM is helping to address financing, manufacturing, procurement,
logistics, delivery and consumer education issues through preparedness studies. IPM is also
exploring ways to use existing delivery or fulfillment systems for consumer products to distribute
microbicides, and is conducting product attribute studies to determine women's preferences for a
variety of gel formulations (see page 14).

"I often feel like I have nothing real to offer women who want to protect themselves. When
microbicides become a reality we will really have something to say to the women. I can't wait!"
MERCY WAHOME, CO-ORDINATOR OF SOCIETY FOR WOMEN AND AIDS IN KENYA (SWAK)
A central element of IPM's access work is a programme of country preparedness studies,
designed to assess considerations in different country settings. It consists of three components:
(1) a country preparedness assessment tool; (2) country assessments; and, (3) follow up actions.
The country preparedness assessment tool identifies issues and actions at the country level to
prepare for rapid availability of microbicides. The tool is being tested and adapted and will be
applicable in a range of country settings. Results from its application will provide country-specific
information and analysis, and map steps for expediting microbicide availability in each setting.
Working in partnership with a consortium of groups in Johannesburg, headed by Health and
Development Africa, and JHPIEGO in Lusaka, IPM initiated the first two country assessments in
South Africa and Zambia. These assessments are being conducted through programmatic
research, policy review, and targeted interviews. The reports are being finalized and stakeholder
meetings are being arranged for mid-2005 that will allow for review and dissemination of
findings. IPM is also actively working to identify appropriate collaborators to conduct similar
assessments in Nigeria and India, and anticipates initiating two additional country case studies in
the coming year.
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In 2004, IPM completed a collaborative project with EngenderHealth, the University of Cape
Town and the Population Council to explore the views of South African community members,
providers and policy makers about potential barriers and opportunities related to the introduction
of microbicides. Through in-depth interviews and focus group discussions, this study and a
subsequent publication explored and identified issues that could facilitate or undermine access to
and use of microbicides. The study was presented at several meetings including Microbicides
2004, and has been submitted for publication.
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Global Advocacy, Policy and
Resource Mobilization
IPM is working to create awareness and support for microbicides and to pave the way
for clinical trials in developing countries. IPM is actively mobilizing resources and seeking
support from policy makers and advocates with the potential to influence national,
international and multilateral decisions.
In 2004, IPM’s External Affairs and Policy Team focused on building strategic
relationships with donors and collaborators to advance the microbicide agenda as
quickly and efficiently as possible. IPM works with groups such as the UNAIDS’ Global
Coalition on Women and AIDS, the Global Campaign for Microbicides and the
Alliance for Microbicide Development to build an international network of champions
and advocates. IPM aims to expand global recognition of microbicides as an essential
component of a comprehensive response to the AIDS pandemic, attract financial support
for microbicide research and development, and prepare for their introduction.

"I ask only that you see microbicides, not merely as one of the great scientific pursuits of the
age, but as a significant emancipation for women whose cultural and social and economic
inheritance have put them so gravely at risk."
STEPHEN LEWIS, UN SPECIAL ENVOY FOR HIV/AIDS IN AFRICA
IPM participated in the biennial microbicides conference, Microbicides 2004, held in
London and attended by more than 700 researchers, public health workers and
advocacy organizations from 50 countries. The biennial forum provided an important
stage for sharing innovation and updates on research and development. In June 2004,
IPM participated in a meeting in Dublin co-hosted by the then Irish Presidency of the EU
and the Netherlands entitled, "New Preventive Technologies: Providing New Options to
Stop the Spread of HIV/AIDS." There, the governments of the Netherlands, Luxembourg
and the United Kingdom, the next three successive presidencies of the European Union,
committed to continued emphasis on HIV during their presidencies.
The XV International AIDS Conference in Bangkok in July 2004 provided a forum for
microbicides, serving to dramatically increase awareness. Influential leaders such as UN
Secretary General Kofi Annan called on the world to ensure that women have full access
to practical prevention options, including microbicides.
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Late in 2004, IPM was in the final stages of securing future funding commitments from
Canada, the European Commission and the United States, adding to the support from
Denmark, Ireland, the Netherlands, Norway, the United Kingdom, Sweden, the Bill &
Melinda Gates Foundation, The Rockefeller Foundation, The World Bank and the United
Nations, thus bringing total commitments to IPM to US $119 million for the period 20022007. After the close of 2004, early in 2005, IPM received formal commitments from
Canada, the European Commission and the United States.
IPM will continue to raise awareness of microbicides in both developed and developing
countries, as well as highlight the need for governments to invest in their development and
access. IPM will take an active role in raising the profile in the international media and at
the policy level by drafting policy papers on the relationship between microbicides and
realization of the Millennium Development Goals, the importance of G8 support for
microbicides as they develop their agenda in 2005 and the importance of advance
purchase mechanisms for new prevention technologies such as vaccines and
microbicides.
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"We must ensure [women] have full access to the practical options that can protect them from HIV—
including microbicides, as they become available."
KOFI ANNAN, UN SECRETARY GENERAL

The XV International AIDS Conference in Bangkok, Thailand, was a
watershed event for microbicides. The issue of women and AIDS and
the potential for microbicides gained wide attention and, for the first
time, provided a forum for microbicide advocates to be heard globally.
This was the ideal venue for IPM to introduce its mission to develop
microbicides for women in the developing world. Through newly
produced materials in English and French, including a brochure and
website, IPM was able to begin sharing its message with a variety of key
audiences including non-governmental organizations, press, policy
makers and more.
IPM hosted a media briefing as well as an event for donors to update
them on IPM's progress and the state of the microbicide field. IPM CEO,
Zeda Rosenberg, delivered a plenary address: "State of the Art Report
on Development and Use of Microbicides," and fielded interest from
several international news organizations that ultimately covered
microbicides in outlets as wide ranging as The Economist, Le Monde,

The New York Times, The Guardian, the Globe and Mail and The Times
of India.

Conference

XV International AIDS
19
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Financials
Statement of Financial Position Year Ending December 31, 2004

ASSETS

REVENUE

Current Assets
Cash
Short-term investments
Pre-paid expenses

$ 11,079,043
25,529,609
52,711

Total Current Assets

36,661,363

Furniture, Equipment, and
Leasehold Improvements
less accumulated
depreciation of $93,720

890,932

Pre-paid Rent and Maintenance

590,916

Security Deposit

73,750

TOTAL ASSETS

$ 38,216,961

Total Current Liabilities
Net Assets
Unrestricted
Total Net Assets
TOTAL LIABILITIES AND NET ASSETS

Contributions
Interest and other revenue
Unrealized gain on investments
Unrealized currency translation

$ 29,088,989
108,290
61,577
13,536

TOTAL REVENUE

$ 29,272,392

EXPENSES

LIABILITIES AND NET ASSETS
Current Liabilities
Accounts payable
Accrued expenses
Payroll withholdings

Unrestricted

$ 958,959
37,792
7,020

Programme Services
Access
Clinical/regulatory affairs
External affairs/policy
Research and development

$ 170,076
2,248,149
1,316,012
3,509,999

Total Programme Services

7,244,236

Supporting Services
General and administrative
Fundraising

1,681,396
216,031

Total Supporting Services

1,897,427

TOTAL EXPENSES

$ 9,141,663

1,003,771
37,213,190
37,213,190
$ 38,216,961

CHANGE IN NET ASSETS

$ 20,130,729

NET ASSETS AT THE BEGINNING OF YEAR

17,082,461

NET ASSETS AT THE END OF YEAR

37,213,190

IPM’s financial statements are audited by Kamerow, Weintraub & Swain, LLP.
The complete audited statements are available upon request to the Chief Financial Officer.
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Current Board, Advisors and Donors
BOARD OF
DIRECTORS

Dr. Quarraisha Abdool Karim
Dr. Els Borst-EEilers (Chair)

Director - Columbia Southern African Fogarty International HIV/AIDS Training
and Research Programme, SOUTH AFRICA
Former Minister of Health, Welfare and Sport and Deputy Prime Minister,
THE NETHERLANDS

Dr. Alex Coutinho (Vice-C
Chair)
Dr. Mahmoud Fathalla
Dr. Henry Gabelnick (Secretary)

Chief Executive Officer - The AIDS Service Organization, UGANDA
Professor of Obstetrics and Gynecology - Assiut University, EGYPT
Director - CONRAD Program, USA

Mr. Rajat Gupta

Senior Partner Worldwide - McKinsey and Company, USA

Dr. Seth Harrison

Managing General Partner - Apple Tree Partners, USA

Dr. Argeris N. (Jerry) Karabelas
Dr. David Kessler
Ms. Anjali Nayyar

Partner - Care Capital, USA
Dean - University of California, San Francisco School of Medicine, USA
Vice President of Country and Regional Programmes - International AIDS
Vaccine Initiative, USA

Dr. Zeda Rosenberg

Chief Executive Officer - IPM, USA

Dr. Hélène Rossert-B
Blavier

Director General - AIDES, FRANCE

Mr. Ayorinde Ajayi Chair - Regional Director for sub-Saharan Africa for the Population Council, USA
ACCESS
ADVISORY
Ms. Lori Heise Director - Global Campaign for Microbicides, USA
COMMITTEE Ms. Elizabeth McGrory Consultant - IPM, USA
Ms. Anjali Nayyar
Dr. Tobias Rinke de Wit
Dr. Roy Widdus

Vice President of Country and Regional Programmes - International AIDS Vaccine Initiative, USA
Director of Operations - Operations PharmAccess International, THE NETHERLANDS
Consultant, Global Health Futures Network, SWITZERLAND

DONORS
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Bill & Melinda Gates Foundation

Norwegian Royal Ministry of Foreign Affairs

Canadian International Development Agency

The Rockefeller Foundation

Department for International Development, United Kingdom

Royal Danish Ministry of Foreign Affairs

Development Cooperation Ireland

Swedish Ministry for Foreign Affairs

European Commission

United States Agency for International Development

The Netherlands Ministry of Foreign Affairs

The World Bank

SCIENTIFIC
ADVISORY
BOARD

Dr. Salim Abdool Karim

Director, Centre for the AIDS Programme of Research, University of KwaZulu-Natal, SOUTH AFRICA

Dr. Richard Bax

Vice President, European Medical Group, Chiron Corporation, UNITED KINGDOM

Dr. Chris Beyrer

Associate Professor of Epidemiology and International Health, Johns Hopkins Bloomberg School of Health
Director, JHU Fogarty AIDS International Training and Research Program
Director, The Center for Public Health and Human Rights, JHU, USA

Dr. Tsungai Chipato

Senior Lecturer in Obstetrics and Gynaecology, College of Health Sciences, University of Zimbabwe
Principal Investigator, University of Zimbabwe-UCSF HIV Prevention Trials Unit, ZIMBABWE

Dr. Robert Coombs

Professor, Laboratory Medicine & Medicine, University of Washington, USA

Dr. Gustavo Doncel

Director of CONRAD Preclinical Research and Associate Professor of Obstetrics and Gynecology, Eastern
Virginia Medical School, USA

Dr. Thomas Folks

Chief, HIV and Retrovirology Branch Division of AIDS, STD, and Laboratory Research, National Center for
Infectious Diseases, Centers for Disease Control and Prevention, USA

Dr. Sanjay Garg

Associate Professor and Deputy Head, School of Pharmacy, University of Auckland, NEW ZEALAND

Dr. Scott Hammer

Professor of Medicine and Public Health (Epidemiology), Columbia University, USA

Dr. Betsy Herold

Professor of Pediatrics & Microbiology, Mount Sinai School of Medicine, USA

Dr. Sharon Hillier

Professor, Magee-Women's Hospital at the University of Pittsburgh, USA

Mr. Chris Irwin
Dr. Newton Kumwenda
Dr. Joep Lange
Dr. Roger LeGrand
Dr. Karl Malcolm

Associate Director, Skin Care Product Development, Procter & Gamble, USA
Epidemiologist, College of Medicine, MALAWI
Professor of Medicine, Center for Poverty-related Communicable Diseases, Academic Medical Center,
University of Amsterdam, THE NETHERLANDS
Head of Neurovirology Department, Commissariat à l'Energie Atomique, DSV/DRM, FRANCE
Lecturer in Pharmaceutics, School of Pharmacy, Queen's University of Belfast, NORTHERN IRELAND

Dr. Kenneth Mayer

Professor of Medicine and Community Health, Brown University/Miriam Hospital, USA

Dr. Ian McGowan

Associate Professor of Medicine, University of California at Los Angeles, David Geffen School of Medicine, USA

Dr. Sanjay Mehendale
Dr. John Mellors
Mr. Jay Nash
Dr. Lynn Paxton
Prof. Helen Rees
Dr. Robin Shattock

Deputy Director, Division of Epidemiology, National AIDS Research Institute, INDIA
Chief, Division of Infectious Diseases and Director of the HIV/AIDS Program, University of Pittsburgh
Medical Center, USA
Principal Scientist, Procter & Gamble, USA
Chief, Sexual Transmission and Injection Drug Use Studies Section, DHAP-SE, Centers for Disease Control
and Prevention, USA
Executive Director, Reproductive Health and HIV Research Unit, Witwatersrand University, SOUTH AFRICA
Reader in Cell Biology of Infection, Center for Infection, Department of Cellular and Molecular Medicine,
St. George's Hospital Medical School, University of London, UNITED KINGDOM

Mr. Paul Tanner

Research Fellow, Procter & Gamble, USA

Dr. Ron Veazey

Professor of Pathology, Tulane University School of Medicine
Chair, Division of Comparative Pathology, Tulane National Primate Research Center, USA

Dr. Mark Wainberg

Director, McGill University AIDS Centre, CANADA

Dr. David Woolfson

Professor of Pharmaceutics, Queen’s University of Belfast, NORTHERN IRELAND
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2004 International Collaborators and Partners
R&D:
Biosyn, Inc., USA
European Microbicide Project, United Kingdom
GlaxoSmithKline, United Kingdom
ImQuest BioSciences, USA
National Institute of Allergy and Infectious Diseases, USA
Particle Sciences, USA
Population Council, USA
Queen's University of Belfast, Northern Ireland
St. George's Hospital Medical School, United Kingdom
Tibotec BVBA, Belgium
Tibotec Pharmaceuticals, Ltd., Ireland
University of Utah, USA
Warner Chilcott, Northern Ireland facility

Access:
EngenderHealth, USA
Health and Development Africa, South Africa
JHPIEGO, Zambia
Population Council, USA
University of Cape Town, South Africa

Current and potential clinical trial sites
IPM Donors
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Clinical Sites and Studies:
CONRAD, USA
Family Health International, USA
FARMOVS-Parexel, South Africa/Multinational
Harvard School of Public Health, USA
Imperial College, United Kingdom
International Antiviral Therapy Evaluation Center, The Netherlands
Kilimanjaro Reproductive Health Programme, Tanzania
Microbicide Development Programme, United Kingdom
MRC/UVRI Uganda Research Unit, Uganda
Projet Ubuzima, Rwanda
Quintiles, South Africa
SGS-Medisearch International N.V., Belgium
Triclinium, South Africa
University of Ghent, Belgium
University of the Free State, South Africa
University of the Witwatersrand, Reproductive Health and HIV Research Unit, South Africa
University of York, United Kingdom

Global Advocacy:
AIDS Fondet, Denmark
Alliance for Microbicide Development, USA
DSW, Germany
Global Campaign for Microbicides, USA
Interagency Coalition on AIDS and Development, Canada
National AIDS Trust, United Kingdom
UNAIDS' Global Coalition on Women and AIDS, Switzerland

Regulatory Affairs:
Social & Scientific Systems, Inc., USA
Triclinium, South Africa
World Health Organization, Switzerland
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HEADQUARTERS:
International Partnership for Microbicides, Inc.
1010 Wayne Avenue
Suite 1450
Silver Spring, MD 20910
USA
Tel: +1-301-608-2221
Fax: +1-301-608-2241
IPM BELGIUM:
Rue du Trône, 98, 7th floor
1050 Brussels
Belgium
Tel: +32(0)2 507 1224
Fax: +32(0)2 507 1222

www.ipm-microbicides.org

